Biochemistry of major human histocompatibility antigens

Cell Surface B2m-Free Human Leukocyte Antigen (HLA) Monomers and Dimers: Are They Neo-HLA Class and Proto-HLA?

Cell surface HLA-I molecules (Face-1) consist of a polypeptide heavy chain (HC) with two groove domains (G domain) and one constant domain (C-domain) as well as a light chain, B2-microglobulin (B2m). However, HCs can also independently emerge unfolded on the cell surface without peptides as B2m-free HC monomers (Face-2), B2m-free HC homodimers (Face 3), and B2m-free HC heterodimers (Face-4). The transport of these HLA variants from ER to the cell surface was confirmed by antiviral antibiotics that arrest the release of newly synthesized proteins from the ER. Face-2 occurs at low levels on the normal cell surface of the lung, bronchi, epidermis, esophagus, breast, stomach, ilium, colorectum, gall bladder, urinary bladder, seminal vesicles ovarian epithelia, endometrium, thymus, spleen, and lymphocytes. They are upregulated on immune cells upon activation by proinflammatory cytokines, anti-CD3 antibodies, antibiotics (e.g., ionomycin), phytohemagglutinin, retinoic acid, and phorbol myristate acetate. Their density on the cell surface remains high as long as the cells remain in an activated state. After activation-induced upregulation, the Face-2 molecules undergo homo- and hetero-dimerization (Face-3 and Face-4). Alterations in the redox environment promote dimerization. Heterodimerization can occur among and between the alleles of different haplotypes. The glycosylation of these variants differ from that of Face-1, and they may occur with bound exogenous peptides. Spontaneous arthritis occurs in HLA-B27+ mice lacking B2m (HLA-B27+ B2m-/-) but not in HLA-B27+ B2m+/- mice. The mice with HLA-B27 in Face-2 spontaneous configuration develop symptoms such as changes in nails and joints, hair loss, and swelling in paws, leading to ankyloses. Anti-HC-specific mAbs delay disease development. Some HLA-I polyreactive mAbs (MEM series) used for immunostaining confirm the existence of B2m-free variants in several cancer cells. The upregulation of Face-2 in human cancers occurs concomitantly with the downregulation of intact HLAs (Face-1). The HLA monomeric and dimeric variants interact with inhibitory and activating ligands (e.g., KIR), growth factors, cytokines, and neurotransmitters. Similarities in the amino acid sequences of the HLA-I variants and HLA-II β-chain suggest that Face-2 could be the progenitor of both HLA classes. These findings may support the recognition of these variants as a neo-HLA class and proto-HLA.

Fluid lamellar keratoplasty in keratoconus

OBJECTIVE

The authors evaluated the efficacy of the modified technique of fluid deep lamellar keratoplasty in keratoconus.

DESIGN

Noncomparative case series.

PARTICIPANTS

Twenty-six eyes of 25 patients with moderate to advanced keratoconus were included. Fourteen males and 11 females with age range of 16 to 37 years.

INTERVENTION

Deep lamellar keratoplasty aided by intrastromal injection of balanced salt solution to facilitate corneal dissection down to Descemet's membrane. Full-thickness graft devoid of endothelium and Descemet's membrane was then sutured in place.

MAIN OUTCOME MEASURES

Spectacle-corrected visual acuity, slit-lamp biomicroscopy, corneal topography, and ocular tension.

RESULTS

Two cases (8.4%) were converted to penetrating keratoplasty because of intraoperative perforation. Of the 24 successful cases, 19 eyes (79%) achieved >20/50 at 3 months and 21 (87.5%) achieved >20/40 at 6 months. Twenty-three eyes (95.8%) were 20/30 or better 1 year after suture removal. Only one eye (4.2%) had interface irregular astigmatism corrected by contact lens to 20/40.

CONCLUSIONS

Fluid deep lamellar keratoplasty is a safe and effective procedure, especially in bilateral keratoconus, because it has no rejection complication. However, it is technically difficult with slow visual rehabilitation.

Treatment of severe cutaneous lupus erythematosus with a chimeric CD4 monoclonal antibody, cM-T412

BACKGROUND

Monoclonal CD4 antibodies are among the most potent immunomodulatory agents in various experimental models of autoimmune disease, including murine lupus erythematosus.

OBJECTIVE

The aim of this study was to evaluate the toxicity and therapeutic efficacy of a chimeric monoclonal CD4 antibody, cM-T412, in patients with cutaneous lupus erythematosus (LE).

METHODS

Five patients with severe cutaneous LE lesions received intravenously a total of 275, 400, or 475 mg of cM-T412 in single doses of 20 to 50 mg during a period of 5 to 8 weeks.

RESULTS

CD4 antibody treatment induced a long-lasting decrease in disease activity. It resulted in healing of LE skin lesions, a reconstituted responsiveness to conventional treatment, or both. Despite a substantial depletion of circulating CD4+ T lymphocytes, no clinical signs of immunosuppression were noted.

CONCLUSION

Monoclonal CD4 antibodies should be considered as a novel treatment for the management of severe cutaneous LE.

Corneal transplantation--immunologically privileged status

Despite the relatively high success rate and the word 'immunologically privileged site', it has been known that a corneal graft can induce an allograft rejection reaction. This is especially true in the rat where orthotopic penetrating corneal grafts in certain strain combinations are rejected even when transplanted in avascular bed. Reliable microsurgical techniques, together with the availability of inbred or congenic strains and a rapidly developing knowledge of its major histocompatibility complex (MHC) and immune system in general, have made the rat a prime species in which to study the immunological events after corneal grafting. This review describes recent progress in understanding the immunological mechanisms behind corneal graft rejection. The topics discussed include the rat MHC (RT1) antigens and their distribution in the cornea; different responder status in fully allogeneic strain combinations, including the importance of multiple non-MHC antigens; and the role of antigen-presenting cells (APCs) in corneal graft rejection.

Plasma membrane glycoproteins of cultured rheumatoid synovial fibroblasts

Fibroblast cultures were started from synovial tissue samples of 12 rheumatoid arthritic, 9 non-rheumatoid synovitic and 6 control patients. External galactose units of plasma membrane glycoproteins of confluent cells were labelled using the galactose oxidase-tritiated borohydride method. These surface-labelled cells were analyzed for possible differences in their glycoproteins by electrophoresis in SDS-containing polyacrylamide gradient gels. Total cell lysates were separated into 50-60 polypeptide bands. Fluorography of the gels revealed about 20 labelled plasma membrane glycoproteins. Some strain-specific differences were detected between the samples in all the groups, but no correlation with rheumatoid arthritis could be demonstrated.

Detection of Ia epitopes by monoclonal antibody blotting

Monoclonal antibodies directed against human Ia alpha- and beta-subunit chains have been used as probes to detect polypeptides carrying recognized antigenic determinants or epitopes following two-dimensional PAGE separation. Approximately 4 sets of components differing in isoelectric point but not in molecular weight are recognized by each antibody. The anti-alpha-chain, McAb, reacts weakly with spots designated as epsilon but neither antibody recognizes Im, Ii or delta determinants under the conditions tested.

A hybridoma monoclonal antibody which reacts with cells carrying the HLA-A2 antigen: evidence for heterogeneity in the expression of HLA-A2

A monoclonal antibody, FMC 5, has been prepared against human lymphocytes and its reactivity examined. FMC 5 behaves, for the most part, as an anti-HLA-A2 typing serum. However, three small groups of discrepant types were identified, and each provides additional insight into the complexity of the MHC antigens. A small number (5/60) of donors typed as HLA-A2 did not react with FMC 5. A further group (6/35) were HLA-A2 and did react with FMC 5, but lysis was always incomplete in this group. Finally, 13/39 non-A2 donors gave various degrees of reactivity with FMC 5. Lysis in this group was usually incomplete and required a high antibody concentration.